Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.

ABSTRACT:

Background

Randomized clinical trials (RCTs) in hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively) are important for the evaluation of new antimicrobials. However, the heterogeneity in endpoints used in RCTs evaluating treatment of HABP/VABP may puzzle clinicians. The aim of this work was to reach a consensus on clinical endpoints to consider in future clinical trials evaluating antimicrobial treatment efficacy for HABP/VABP.

Methods

Twenty-six international experts from intensive care, infectious diseases, and the pharmaceutical industry were polled using the Delphi method.

Results

The panel recommended a hierarchical composite endpoint including, by priority order, (1) survival at day 28, (2) mechanical ventilation-free day

SUBMITTER: Weiss E 

PROVIDER: S-EPMC9431655 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature